B86
Conditions
Interventions
Group 1: Benzyl benzoate 25% Emulsion
Group 2: Permethrin 5% Ointment
Sponsors
UK f. Dermatologie und Allergologie Salzburg
Eligibility
Sex/Gender
All
Age
12 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Scabies with light microscopic mite detection. - Age: from 12 years of age (treatment by parent until physical/cognitive development allows self-treatment)
Exclusion criteria
Exclusion criteria: - Scabies norvegica/crustosa - Pre-treatment of creams/emulsions containing benzyl benzoate (Antiscabiosum® 25%) in the last 3 weeks (from first application) - Application of creams containing permethrin (e.g. Infectoscab® 5%) during the last 3 weeks (from first application) - Use of oral ivermectin in the last 3 weeks. -- EXCEPTION: Children from the age of 12 to 18 years or study participants with a high mite density (>5 mites with duct structures in the reflected light microscope field of view) may be treated with topical benzyl benzoate, topical benzyl benzoate, topical benzyl benzoate, topical benzyl benzoate benzyl benzoate, topical permethrin or oral ivermectin may be included - known hypersensitivity to the active ingredient benzyl benzoate or permethrin - Patients who, because of their physical development or clinical condition, are unable to receive Are unable to understand and correctly perform the treatment procedures - Pregnancy and lactation - Alcohol abuse, mental retardation - Lack of willingness to comply/adhere to appointments as well as the Study protocol, and lack of understanding of the German language.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy | — |
Secondary
| Measure | Time frame |
|---|---|
| Tolerance | — |
Countries
Austria
Contacts
Public ContactMatthias Brandlmaier
UK f. Dermatologie und Allergologie Salzburg
Outcome results
None listed